keyword
MENU ▼
Read by QxMD icon Read
search

urothelium cancer

keyword
https://www.readbyqxmd.com/read/28916750/comprehensive-multiregional-analysis-of-molecular-heterogeneity-in-bladder-cancer
#1
Mathilde Borg Houlberg Thomsen, Iver Nordentoft, Philippe Lamy, Søren Vang, Line Reinert, Christophe Kamungu Mapendano, Søren Høyer, Torben F Ørntoft, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
Genetic alterations identified in adjacent normal appearing tissue in bladder cancer patients are indicative of a field disease. Here we assessed normal urothelium transformation and intra-tumour heterogeneity (ITH) in four patients with bladder cancer. Exome sequencing identified private acquired mutations in a lymph node metastasis and local recurrences. Deep re-sequencing revealed presence of at least three and four subclones in two patients with multifocal disease, while no demarcation of subclones was identified in the two patients with unifocal disease...
September 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28888113/tissue-engineered-human-3d-model-of-bladder-cancer-for-invasion-study-and-drug-discovery
#2
Cassandra Ringuette Goulet, Geneviève Bernard, Stéphane Chabaud, Amélie Couture, Alexandre Langlois, Bertrand Neveu, Frédéric Pouliot, Stéphane Bolduc
The tumour microenvironment is critical to both the initiation and maintenance of tumorigenesis. Reconstitution of the microenvironment is a major challenge for in vitro cancer models. Indeed, conventional 2D culture systems cannot replicate the complexity, diversity and dynamic nature of the tumour microenvironment. In this study, we have developed a 3D endotheliazed vesical equivalent by using tissue engineering from primary human cells in which non-invasive or invasive bladder cancer (BCa) cell lines, cultured as compact spheroids, were incorporated...
August 29, 2017: Biomaterials
https://www.readbyqxmd.com/read/28882129/igf1r-activation-and-the-in-vitro-antiproliferative-efficacy-of-igf1r-inhibitor-are-inversely-correlated-with-igfbp5-expression-in-bladder-cancer
#3
Yann Neuzillet, Elodie Chapeaublanc, Clémentine Krucker, Leanne De Koning, Thierry Lebret, François Radvanyi, Isabelle Bernard-Pierrot
BACKGROUND: The insulin growth factor (IGF) pathway has been proposed as a potential therapeutic target in bladder cancer. We characterized the expression of components of the IGF pathway - insulin growth factor receptors (INSR, IGF1R, IGF2R), ligands (INS, IGF1, IGF2), and binding proteins (IGFBP1-7, IGF2BP1-3) - in bladder cancer and its correlation with IGF1R activation, and the anti-proliferative efficacy of an IGF1R kinase inhibitor in this setting. METHODS: We analyzed transcriptomic data from two independent bladder cancer datasets, corresponding to 200 tumoral and five normal urothelium samples...
September 7, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28871659/overexpression-of-her-2-via-immunohistochemistry-in-canine-urinary-bladder-transitional-cell-carcinoma-a-marker-of-malignancy-and-possible-therapeutic-target
#4
F Millanta, J Impellizeri, L McSherry, G Rocchigiani, L Aurisicchio, G Lubas
Transitional cell carcinoma (TCC) is the most commonly diagnosed neoplasm in the urinary bladder. Distant metastases to the regional lymph nodes, lungs, abdominal organs or bones are noted in up to 50% of dogs at time of death. Surgical excision is often not practical as TCC typically involve the trigone of the bladder and/or occurs multifocally throughout the bladder with field cancerization. Therapeutic approaches are very challenging and the requirement to evaluate alternative therapeutic protocols that may prolong survival times in dogs bearing these tumours is compelling...
September 4, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28843746/cytological-and-histological-changes-in-the-urothelium-produced-by-electromotive-drug-administration-emda-and-by-the-combination-of-intravescical-hyperthermia-and-chemotherapy-thermochemotherapy
#5
Francesco Pierconti, Patrizia Straccia, Sacco Emilio, Pier Francesco Bassi, Ivana De Pascalis, Rita C Marques, Metka Volavsek, Luigi M Larocca, Antonio Lopez-Beltran
The treatment of non muscle-invasive bladder cancer (NMIBC) encompasses a range of different procedures. Electromotive drug administration (EMDA) and chemo-hyperthermia (C-HT; Synergo) represent a minimally-invasive methods of intravesical instillation of therapeutic agents as mitomycin C (MMC). We selected patients with high grade NMIBC, BCG non responder, treated with EMDA/MMC and C-HT/MMC and we also examined the morphological changes in urine cytology samples. During the period from 2012 to 2014, 110 patients with high grade NMIBC, BCG refractory were selected...
August 1, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28831205/phosphorylated-mtor-expression-profiles-in-human-normal-and-carcinoma-tissues
#6
Hojung Lee
Mammalian target of rapamycin (mTOR) is a key controller of cell growth and proliferation in normal tissues and solid tumors. In the present study, an immunohistochemical analysis of the expression pattern of phosphorylated mTOR (p-mTOR) was performed in human normal fetal and adult tissues and various carcinoma tissues. p-mTOR expression showed tissue and cell type specificity in normal and cancer tissues. In normal fetal and adult tissues, p-mTOR staining was observed in the intestinal crypt, intrahepatic bile ductule, pancreatic duct, distal nephron of the kidney, umbrella cell of urothelium, mesothelial cell, and choroid plexus...
2017: Disease Markers
https://www.readbyqxmd.com/read/28818454/the-anti-tumor-effect-of-intravesical-administration-of-normal-urothelial-cells-on-bladder-cancer
#7
Chi-Ping Huang, Chi-Cheng Chen, Chih-Rong Shyr
BACKGROUND AIMS: Urothelial bladder cancer (UBC) is the second most common cancer of the genitourinary tract and for advanced forms of the disease it has a high mortality rate. There are no approved new molecularly targeted agents or chemotherapeutics for advanced UBC beyond cisplatin-based chemotherapy except the recently approved anti-programmed death ligand 1 (anti-PD-1/PD-L1) antibody. With complex genetic and epigenetic alterations in tumors, despite several druggable targets identified, to cure UBC is still a challenging unmet medical need...
August 14, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28816296/-complete-androgen-insensitivity-syndrome-associated-with-vesical-fistula-a-case-report-and-literature-review
#8
K H Hua, L Yang, X W Zhang, W J Bai, Q Li, T Xu
Androgen insensitivity syndrome (AIS) is a very uncommon genetic disorder that results from the resistance of androgen receptor (AR) to androgen, which influences the formation of the male genitalia and in turn presents with female phenotype. Surgical resection of undesceaded testicle and different kinds of genitoplasty are crucial methods to correct the deformity of reproductive system, as well as hormone replacement therapy, which is an essential therapy for postoperational rehabilitation in AIS patients...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28766915/metabolomics-analysis-reveals-distinct-profiles-of-nonmuscle-invasive-and-muscle-invasive-bladder-cancer
#9
Divya Sahu, Yair Lotan, Bryan Wittmann, Bruce Neri, Donna E Hansel
Urothelial carcinoma is the most common form of bladder cancer, but pathway changes that occur with stage-wise progression have not been well defined. We used a metabolomics approach to identify potential metabolic pathways uniquely altered in normal urothelium, nonmuscle-invasive bladder cancer (NMIBC), and muscle-invasive bladder cancer (MIBC). We performed global metabolomic profiling using GC-mass spectrometry (MS) and LC-MS platforms to identify metabolite signatures between normal urothelium and high-grade urothelial carcinoma of different stages...
August 1, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28753897/lack-of-effectiveness-of-postchemotherapy-lymphadenectomy-in-bladder-cancer-patients-with-clinical-evidence-of-metastatic-pelvic-or-retroperitoneal-lymph-nodes-only-a-propensity-score-based-analysis
#10
Andrea Necchi, Luigi Mariani, Salvatore Lo Vullo, Evan Y Yu, Michael E Woods, Yu-Ning Wong, Lauren C Harshman, Ajjaj Alva, Cora N Sternberg, Aristotelis Bamias, Petros Grivas, Vadim S Koshkin, Florian Roghmann, Jakub Dobruch, Bernie J Eigl, Lucia Nappi, Matthew I Milowsky, Guenter Niegisch, Sumanta K Pal, Ugo De Giorgi, Federica Recine, Ulka Vaishampayan, Dominik D Berthold, Daniel W Bowles, Jack Baniel, Christine Theodore, Sylvain Ladoire, Sandy Srinivas, Neeraj Agarwal, Simon Crabb, Srikala Sridhar, Ali-Reza Golshayan, Carsten Ohlmann, Evanguelos Xylinas, Thomas Powles, Johnathan E Rosenberg, Joaquim Bellmunt, Bas van Rhijn, Matthew D Galsky, Kees Hendricksen
BACKGROUND: Limited data is available on the role, and extent of, postchemotherapy lymphadenectomy (PC-LND) in patients with clinical evidence of pelvic (cN1-3) or retroperitoneal (RP) lymph node spread from urothelial bladder carcinoma. OBJECTIVE: To compare the outcomes of operated versus nonoperated patients after first-line chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Data from 34 centers was collected, totaling 522 patients, treated between January 2000 and June 2015...
June 3, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753879/robot-assisted-versus-open-radical-cystectomy-in-patients-receiving-perioperative-chemotherapy-for-muscle-invasive-bladder-cancer-the-oncologist-s-perspective-from-a-multicentre-study
#11
Andrea Necchi, Gregory R Pond, Marc C Smaldone, Sumanta K Pal, Kevin Chan, Yu-Ning Wong, Rosalia Viterbo, Guru Sonpavde, Lauren C Harshman, Simon Crabb, Ajjai Alva, Simon Chowdhury, Ugo De Giorgi, Sandy Srinivas, Neeraj Agarwal, Aristotelis Bamias, Jack Baniel, Ali-Reza Golshayan, Sylvain Ladoire, Cora N Sternberg, Linda Cerbone, Evan Y Yu, Joaquim Bellmunt, Ulka Vaishampayan, Gunter Niegisch, Syed Hussain, Daniel W Bowles, Rafael Morales-Barrera, Matthew I Milowsky, Christine Theodore, Dominik R Berthold, Srikala S Sridhar, Thomas Powles, Jonathan E Rosenberg, Matthew D Galsky
BACKGROUND: Little is known about the outcomes of robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) combined with perioperative chemotherapy for muscle-invasive urothelial bladder cancer (UBC). OBJECTIVE: To evaluate surgical and oncological outcomes for RARC and ORC in multimodal treatment. DESIGN, SETTING, AND PARTICIPANTS: Data from 28 centres were collected for cystectomies performed between January 2000 and July 2013...
March 31, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28751166/clinical-and-demographic-characteristics-among-patients-with-urothelial-carcinomas-of-the-upper-urinary-tract-and-bladder-in-taiwan
#12
Cheng-Huang Shen, Hung-Yi Chiou, Min-Che Tung, Chia-Chang Wu, Wei-Tang Kao, Yuan-Hung Wang, Guang-Dar Juang
BACKGROUND: Urothelial carcinoma (UC) is derived from the urothelium of the urinary tract, and includes cancers of the bladder, renal pelvis and ureter. The aim of this study was to investigate the clinical and demographic features among patients with bladder cancer and urothelial carcinoma of the upper urinary tract (UTUC) in Taiwan. METHODS: The present study recruited a total of 736 histopathologically confirmed UC cases, which consisted of 470 bladder cancer and 266 UTUC between September 1998 and December 2009...
July 24, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28749907/immunotherapy-in-urothelial-cancer-part-1-t-cell-checkpoint-inhibition-in-advanced-or-metastatic-disease
#13
Steven S Yu, Tanya B Dorff, Leslie K Ballas, Sarmad Sadeghi, Eila C Skinner, David I Quinn
Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this disease present as non-muscle-invasive bladder cancer (NMIBC), with cancer recurrence or progression to muscle-invasive cancer in more than 50% of patients after initial therapy. NMIBC is an immune-responsive disease, as indicated by the use of intravesical bacillus Calmette-Guérin as treatment for more than 3 decades. More recently, immunotherapy has seen much progress in a variety of cancers, including advanced and metastatic bladder cancer, in which historical 5-year survival rates are approximately 15%...
June 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28724419/real-life-clinical-practice-results-with-vinflunine-in-patients-with-relapsed-platinum-treated-metastatic-urothelial-carcinoma-an-italian-multicenter-study-movie-goirc-01-2014
#14
Rodolfo Passalacqua, Silvia Lazzarelli, Maddalena Donini, Rodolfo Montironi, Rosa Tambaro, Ugo De Giorgi, Sandro Pignata, Raffaella Palumbo, Giovanni Luca Ceresoli, Gianluca Del Conte, Giuseppe Tonini, Franco Morelli, Franco Nolè, Stefano Panni, Ermanno Rondini, Annalisa Guida, Paolo Andrea Zucali, Laura Doni, Elisa Iezzi, Caterina Caminiti
BACKGROUND: Vinflunine is the only chemotherapeutic agent shown to improve survival in platinum-refractory patients with metastatic transitional cell carcinoma of the urothelium (TCCU) in a phase III clinical trial, which led to product registration for this indication in Europe. The aim of this study was to assess the efficacy of vinflunine and to evaluate the prognostic significance of risk factors in a large, unselected cohort of patients with metastatic TCCU treated according to routine clinical practice...
July 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28716122/systematic-evaluation-of-oligodeoxynucleotide-binding-and-hybridization-to-modified-multi-walled-carbon-nanotubes
#15
Anika Kaufmann, Silke Hampel, Christiane Rieger, David Kunhardt, Darja Schendel, Susanne Füssel, Bernd Schwenzer, Kati Erdmann
BACKGROUND: In addition to conventional chemotherapeutics, nucleic acid-based therapeutics like antisense oligodeoxynucleotides (AS-ODN) represent a novel approach for the treatment of bladder cancer (BCa). An efficient delivery of AS-ODN to the urothelium and then into cancer cells might be achieved by the local application of multi-walled carbon nanotubes (MWCNT). In the present study, pristine MWCNT and MWCNT functionalized with hydrophilic moieties were synthesized and then investigated regarding their physicochemical characteristics, dispersibility, biocompatibility, cellular uptake and mucoadhesive properties...
July 17, 2017: Journal of Nanobiotechnology
https://www.readbyqxmd.com/read/28638274/hypoxia-regulated-microrna-210-overexpression-is-associated-with-tumor-development-and-progression-in-upper-tract-urothelial-carcinoma
#16
Hung-Lung Ke, Wei-Ming Li, Hui-Hui Lin, Wei-Chi Hsu, Ya-Ling Hsu, Lin-Li Chang, Chun-Nung Huang, Ching-Chia Li, Hsin-Ping Chang, Hsin-Chih Yeh, Chien-Feng Li, Wen-Jeng Wu
BACKGROUND: Hypoxia has been shown to facilitate tumor progression. Hypoxia-regulated microRNA-210 (miR-210) may play an important role in carcinogenesis and tumor progression. In this study, we evaluated the clinical significance of miR-210 expression in upper tract urothelial carcinoma (UTUC). METHODS: Eighty-three UTUC patients participated in this study. All of them provided cancer tissue samples and 50 of them provided non-cancerous urothelium samples. Clinicopathologic data were collected by reviewing medical records...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28637487/the-nf1-somatic-mutational-landscape-in-sporadic-human-cancers
#17
REVIEW
Charlotte Philpott, Hannah Tovell, Ian M Frayling, David N Cooper, Meena Upadhyaya
BACKGROUND: Neurofibromatosis type 1 (NF1: Online Mendelian Inheritance in Man (OMIM) #162200) is an autosomal dominantly inherited tumour predisposition syndrome. Heritable constitutional mutations in the NF1 gene result in dysregulation of the RAS/MAPK pathway and are causative of NF1. The major known function of the NF1 gene product neurofibromin is to downregulate RAS. NF1 exhibits variable clinical expression and is characterized by benign cutaneous lesions including neurofibromas and café-au-lait macules, as well as a predisposition to various types of malignancy, such as breast cancer and leukaemia...
June 21, 2017: Human Genomics
https://www.readbyqxmd.com/read/28627636/formulation-and-characterization-of-egcg-for-the-treatment-of-superficial-bladder-cancer
#18
Katarzyna Dettlaff, Maciej Stawny, Magdalena Ogrodowczyk, Anna Jelińska, Waldemar Bednarski, Dorota Wątróbska-Świetlikowska, Rick W Keck, Omar A Khan, Ibrahim H Mostafa, Jerzy Jankun
In the United States, the annual incidence of bladder cancer is approximately 70,000 new cases, with a mortality rate of approximately 15,000/year. The most common subtype (70%) of bladder cancer is superficial, namely hte non-muscle invasive disease form limited to the urothelium. The rate of progression and recurrence is up to 40 and 70%, respectively. Urothelial cell carcinoma of the bladder is typically treated with transurethral resection. The cancerous cells can float onto the adjacent epithelium, increasing the risk of recurrence...
June 14, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28588015/intravesical-bcg-induces-cd4-t-cell-expansion-in-an-immune-competent-model-of-bladder-cancer
#19
Max Kates, Thomas Nirschl, Nikolai A Sopko, Hotaka Matsui, Christina M Kochel, Leonardo O Reis, George J Netto, Mohammad Hoque, Noah M Hahn, David J McConkey, Alex S Baras, Charles G Drake, Trinity J Bivalacqua
Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is the standard of care in treating non-muscle-invasive bladder cancer, yet its mechanism of action remains elusive. Both innate and adaptive immune responses have been implicated in BCG activity. Although prior research has indirectly demonstrated the importance of T cells and shown a rise in CD4(+) T cells in bladder tissue after BCG, T-cell subpopulations have not been fully characterized. We investigated the relationship between effector and regulatory T cells in an immune competent, clinically relevant rodent model of bladder cancer...
July 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28579283/optimizing-management-of-upper-tract-urothelial-carcinoma
#20
REVIEW
Matthew T Campbell, Amishi Y Shah, Surena F Matin, Arlene O Siefker-Radtke
Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease...
June 1, 2017: Urologic Oncology
keyword
keyword
53999
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"